CLL, COVID-19, & Why Patient Registries Matter

During the summer months of 2021, community transmission rates of COVID-19 have again surged across the U.S. People with chronic lymphocytic leukemia (CLL) and other blood cancers, who are immunocompromised, face added risk from COVID-19 and need more information on vaccine and booster shot efficacy. In this episode, Gwen Nichols, MD, Chief Medical Officer, the Leukemia & Lymphoma Society (LLS), explains how patients are helping researchers discover these answers through participation in the LLS National Patient Registry and the far-reaching effects their participation will have on improving care for patients with blood cancer.  Guest: Gwen Nichols, MD Chief Medical Officer The Leukemia & Lymphoma Society (LLS) Related Content Returning to Practice in the Post-COVID-19 Era: Resources for Treating Chronic Lymphocytic Leukemia [PODCAST] Ep 61: CLL Patient Education in Transitional Times [PODCAST] Ep 57: COVID-19 Challenges: Managing Patients with CLL [WEBINAR] Learning from COVID-19: Coping Strategies for CLL Providers & Patients [WEBINAR] Plain & Simple: Strategies for Improving Health Literacy Leukemia & Lymphoma Society (LLS) LLS National Patient Registry A study from The Leukemia & Lymphoma Society shows COVID-19 vaccine is safe but 25% of blood cancer patients do not produce detectable antibodies. Read the full paper published in Cancer Cell here.  COVID-19 vaccine safety among blood cancer patients COVID-19 vaccine FAQ for patients and caregivers